Advanced Biomed Inc. Receives Nasdaq Delisting Notice, Files Appeal

summarizeSummary

Advanced Biomed Inc. received a delisting notice from Nasdaq due to non-compliance with the minimum bid price rule, but has filed an appeal to challenge the decision.

check_boxKey Events

• Delisting Notice Received

  Advanced Biomed Inc. received a notice from Nasdaq on January 16, 2026, stating its securities would be delisted and suspended on January 27, 2026, due to failure to meet the minimum $1.00 bid price requirement by the January 14, 2026 deadline.

• Company Appeals Delisting

  On January 21, 2026, the company appealed Nasdaq's delisting determination by submitting a hearing request, which temporarily stayed the suspension and delisting process.

• Reverse Stock Split Planned

  The company plans to present a reverse stock split, approved by stockholders on January 12, 2026, to the Nasdaq Hearings Panel as part of its plan to regain compliance. The split is expected to be effective on or after February 13, 2026.

• Uncertainty of Continued Listing

  There is no assurance that the Panel will grant the company's request for continued listing or that the company will be able to evidence compliance within any granted period.

auto_awesomeAnalysis

Advanced Biomed Inc. has received a delisting notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement. While the company has appealed this determination, which temporarily stays the delisting, the uncertainty of continued listing on Nasdaq poses a significant risk to the company's liquidity and investor confidence. The planned reverse stock split is a common strategy to regain compliance, but its long-term effectiveness in sustaining the share price above the minimum threshold is not guaranteed.